Immuneering (NasdaqGM:IMRX) FY Conference Transcript

Summary of Immuneering's Conference Call Company Overview - Company: Immuneering - Focus: Development of atebimetinib, a novel oral drug candidate aimed at improving survival in first-line pancreatic cancer and other cancers Key Points Industry and Product - Industry: Biopharmaceuticals, specifically oncology - Product: Atebimetinib, categorized as a Deep Cyclic Inhibitor, designed to improve overall survival through three mechanisms: tumor shrinkage, body mass preservation, and side effect minimization [2][28] Clinical Data and Comparisons - Survival Rates: Reported 64% overall survival at 12 months in Phase 2a study, compared to a 35% benchmark for standard care (gemcitabine/nab-paclitaxel) [2][3][10] - Disease Control Rate: 81% in patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel, significantly higher than the 48% benchmark for standard care [6][17] - Progression-Free Survival: 8.5 months, compared to 5.5 months for standard care [16] - Overall Response Rate: 39%, higher than the 23% benchmark from standard care [16] Mechanisms of Action - Three Mechanisms: 1. Tumor Shrinkage: Effective in both RAS and RAF-driven tumors 2. Body Mass Preservation: 84% of patients maintained or gained weight, counteracting cachexia [6][8] 3. Minimizing Side Effects: Only two categories of Grade 3 or higher adverse events (neutropenia and anemia) seen in over 10% of patients [18][19] Future Studies and Trials - Phase 3 Study: MAPKeeper 301, a global randomized pivotal trial, will compare atebimetinib plus modified gemcitabine/nab-paclitaxel against standard care, with overall survival as the primary endpoint [3][27] - Patient Enrollment: Expanded cohort of over 50 patients expected to report data in the first half of 2026 [21][22] Regulatory and Market Position - Regulatory Alignment: Fully aligned with FDA and EMA for the Phase 3 study [3][29] - Market Potential: Targeting a broad range of RAS, RAF, and other MAPK-driven cancers, which account for about half of all tumors [4][30] Key Opinion Leader (KOL) Feedback - KOLs express excitement about the triple mechanism of action, emphasizing its potential to enhance patient quality of life and survival [33][36] Conclusion - Immuneering aims to establish atebimetinib as the new standard of care in first-line pancreatic cancer, leveraging its unique mechanisms to improve patient outcomes and quality of life [46][47]